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Abstract
Objectives To report the prevalence and severity of metamorphopsia, estimate its impact on vision-related quality of life
(VRQoL) and evaluate predictors of VRQoL in patients with vitreomacular traction (VMT).
Patients and methods A prospective, cross-sectional multi-centre study in the United Kingdom of 185 patients with VMT,
with or without a full thickness macular hole (FTMH). Self-reported metamorphopsia was determined using the meta-
morphopsia questionnaire. VRQoL was assessed using the Visual Function Questionnaire (VFQ-25). Physicians recorded
clinical and ocular characteristics in both eyes including a physician assessment of metamorphopsia. ANOVA and predicted
least-squares means were used to estimate the impact of metamorphopsia on VRQoL. Predictors of VRQoL were assessed
using ordinary-least-squares regression adjusting for clinically important variables.
Results The prevalence of self-reported metamorphopsia was 69.7% (95% CI 62.6–76.3%) and was higher in eyes with a
concomitant FTMH vs. without FTMH (85.4% vs. 64.2%). Physician assessment of metamorphopsia was 53.0% (95% CI:
45.5–60.3%). Comparing eyes with metamorphopsia vs. without metamorphopsia, the VFQ-25 composite score was lower
(82.3 vs. 91.4), and mean VA (LogMAR) was worse (0.44 vs. 0.33). The largest difference in VFQ-25 scores was observed
for near activities (metamorphopsia: 75.3, No metamorphopsia: 90.2). The adjusted model showed that metamorphopsia
severity and age were significantly associated with lower VFQ-25 scores.
Conclusion Metamorphopsia was highly prevalent in patients with VMT and associated with significantly lower VRQoL.
Physician assessment of symptoms underestimated the self-reported presence of metamorphopsia. Metamorphopsia severity
acts as a predictor of impaired VRQoL, over and above decrements due to reduced vision.
Introduction
Vitreomacular adhesion (VMA) is characterised by persis-
tent macular attachment of the posterior vitreous within 3
mm of the fovea without an altered foveal contour and
results from incomplete posterior vitreous detachment
(PVD) [1]. VMA may be seen transiently as part of normal
aging and occurs with higher frequency in a variety of
retinal diseases including diabetic retinopathy or age-related
macular degeneration (AMD) [2]. Vitreomacular traction
(VMT) results when VMA is associated with alteration of
foveal morphology including distortion or elevation of the
foveal surface. VMT can resolve spontaneously but per-
sistent VMT is a known risk factor for the development of a
full thickness macular hole (FTMH) and epiretinal mem-
brane (ERM) [3–5]. Patient-reported symptoms of VMT
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include distortion of vision (metamorphopsia) and blurred
vision.
Some studies have investigated metamorphopsia and its
association with vision-related quality of life (VRQoL) in
retinal disorders, however none of these relate to meta-
morphopsia in VMT [6–13]. It could be anticipated that
patients with VMT have similar signs or severity of meta-
morphopsia as patients with other retinal disorders who
have metamorphopsia. Yet, no studies have prospectively
assessed the prevalence and severity of metamorphopsia or
the impact of metamorphopsia on VRQoL in patients with
VMT. Although the Amsler grid allows for a simple qua-
litative evaluation of alterations of visual function [14], the
sensitivity of the test in the early detection of metamor-
phopsia is low; and additionally, the test is known to have a
high false-negative rate [15]. These factors may explain its
limited use in current clinical practice in the UK. Further,
while tools to quantify metamorphopsia such as PHP, M-
charts or D-charts have been developed more recently, these
instruments were not adopted in routine day-to-day clinical
practice.
The aim of the present Metamorphopsia (MeMo) study
was to determine the self-reported prevalence and severity
of VMT-related metamorphopsia in patients presenting to
eye clinics in the United Kingdom (UK), to report the
impact of metamorphopsia on VRQoL, and to explore
possible clinically relevant predictors of VRQoL.
Patients and methods
Study design and setting
The MeMo study was a prospective, observational, cross-
sectional, multi-centre study conducted at NHS hospital eye
clinics across the United Kingdom (UK). Ethical approval
was granted by the West of Scotland Research Ethics Ser-
vice (REC reference number: 14/WS/0092) and institutional
R&D approval was obtained for the protocol and study-
related documents. The study adhered to Good Clinical
Practice and to the tenets of the Declaration of Helsinki.
Informed consent was obtained from every participant prior
to enrolment.
Sites were chosen to provide a representative sample of
VMT patients, specifically, sites from large and small cities
and a wide geographical spread across the UK. Ophthal-
mology clinics operating treatment protocols that included
observation (watchful waiting) and/or pharmacological
(ocriplasmin) or surgical (vitrectomy) vitreolysis were
enroled. Participating physicians had experience with the
diagnosis and treatment of VMT and were characterised by
a mixed referral basis. Treating physicians continued their
usual practice and patient management, no protocol-driven
treatment or test was administered to preserve the obser-
vational design. Recruitment extended from July 1, 2014
until July 1, 2015.
Participants
Inclusion criteria included a confirmed diagnosis of VMT,
with or without a concomitant FTMH, within prior
6 months and ability to provide written informed consent.
Consecutive patients were enroled as they presented for a
routine clinic visit to address potential sources of bias.
Exclusion criteria, assessed in the affected eye, included:
VMT associated with an underlying macular disease (e.g.,
age-related macular degeneration, diabetic retinopathy; ret-
inal vein occlusion); FTMH or epiretinal membrane (ERM)
without a tractional component; traumatic MH; FTMH >
400 μm; high myopia (>8 dioptres); advanced glaucoma;
prior vitrectomy or intravitreal intervention; and intraocular
surgery other than vitrectomy within prior 3 months.
Data collection
Physicians collected baseline data at the single visit for each
participant using a standardised data form consisting of
inclusion/exclusion criteria, patient characteristics, current
medical and ocular conditions, ocular interventions, date of
first symptoms, and ocular examinations. The investigator
noted ocular dominance through asking the patient, using
one of the recommended tests (Miles, Porta, Convergence
near-point, Dolman) or alternatively the test applied in their
clinical practice. In addition, the physician’s assessment of
symptoms (metamorphopsia, blurred vision, curvy objects,
double vision, unable to drive at night, other), ocular
diagnosis and date of diagnosis were recorded. All ocular
assessments were performed for the affected and fellow eye.
Patients completed the metamorphopsia questionnaire and
the National Eye Institute Visual Function Questionnaire,
hence these were all self-reported outcomes.
Assessment of metamorphopsia and vision-related
quality of life
Metamorphopsia questionnaire (MeMoQ)
The primary outcome measure of the MeMo study was the
prevalence of metamorphopsia in patients with VMT. The
presence (and severity) of metamorphopsia was based on
the patient’s self-reported perception of abnormal vision
quality as evaluated using the MeMoQ. The metamor-
phopsia questionnaire, developed by Arimura et al. consists
of ten items focusing on symptoms of subjective meta-
morphopsia in a patient’s daily life [16]. Arimura et al.
previously performed a Rasch analysis to verify the
P. J. Patel et al.
questionnaire’s validity in patients with ERM, MH, AMD,
and healthy controls. The questionnaire was found to be a
valid assessment of patient subjective impression of meta-
morphopsia, and supplemented the clinical detection and
quantification of metamorphopsia [16]. For the purpose of
the MeMo study, we removed one item (‘Do the columns in
your Japanese style rooms appear distorted or tilted to
you?’) which was culturally not relevant in our European
sample (Fig. 1). Consistent with the questionnaire’s scoring
algorithm, the prevalence of metamorphopsia was defined
as a MeMoQ score greater than zero, while severity was
based on the MeMoQ score calculated as the mean score of
non-missing items. Since the validation study found no
difference in results between Rasch scores and total scores,
our analyses were based on raw scores [16].
National Eye Institute Visual Function Questionnaire (NEI
VFQ-25)
Patients completed the self-assessed, self-administered
version of the VFQ-25 to assess VR-QoL. Each of the 25
VFQ questions is assigned to one of the 12 subscales:
general health, general vision, ocular pain, near activities,
distance activities, social functioning, mental health, role
difficulties, dependency, driving, colour vision, and per-
ipheral vision. Subscales scores range from 0 to 100, where
100 indicates the highest possible function or minimal
subjective impairment [17]. The NEI VFQ-25 composite
score was calculated as the average of the subscale scores,
excluding the General Health item [18]. In line with pre-
vious clinical reports, our VFQ-25 analyses were based on
raw scores.
Physician assessment of metamorphopsia
In addition to the primary determination of metamorphopsia
prevalence (self-reported from the MeMoQ), the physi-
cian’s assessment of metamorphopsia was positive if the
patient reported distorted vision and/or curvy objects in
either eye.
Study size
MeMo was a descriptive study with the primary aim of
estimating the prevalence of metamorphopsia in VMT.
Based on a 95% two-sided confidence interval (CI) and an
assumed prevalence between 60 and 90%, a sample size of
approximately 200 allows a precision of the prevalence
estimate within an 8.4–13.6% range.
Statistical methods
The prevalence of metamorphopsia assessed by the
MeMoQ was computed for the overall population and for
subgroups according to the presence of a FTMH. Clopper-
Pearson method was performed to obtain 95% CI around
prevalence estimates. Physician assessment of the presence
of symptoms of metamorphopsia was summarised for the
overall population and by self-reported presence of meta-
morphopsia. The agreement between physician and patient
evaluation of metamorphopsia was calculated using the
Kappa statistic [19]. Descriptive statistics for the VFQ-25
scores were generated for the overall population and by self-
reported presence of metamorphopsia. P values assessing
differences between metamorphopsia subgroups were
derived from the Student’s t-test. Due to the exploratory
nature of this study, no formal hypothesis testing was
conducted. Thus, any P-value generated should be regarded
as a descriptive, rather than inferential, statistic.
The effect of the presence of metamorphopsia on VFQ-
25 was explored through a univariate (ANOVA) model. In
the ANOVA model, the VFQ-25 score was the dependent
variable and an indicator variable denoting presence of
metamorphopsia was the independent variable. The least-
square mean VFQ-25 scores were reported for patients with
metamorphopsia and patients without metamorphopsia. The
Fig. 1 MeMoQ. The 9-item MeMoQ administered in the MeMo study.
The MeMoQ analysis excluded one item (Q7) because of misfit, as
concluded by the developers’ Rasch analysis. In line with the original
validation study, the threshold for presence of metamorphopsia was a
MeMoQ score > 0. Min–Max score: 0–3. As per the scoring algorithm,
the MeMoQ score was calculated as the average of the remaining eight
items using the questionnaire specific response values (“not at all”= 0
points; “a little”= 1 point; “moderately”= 2 points; “a great deal”= 3
points; items marked with “None of the above” were excluded from
the scoring)
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Table 1 Baseline demographic characteristics and ocular findings in the MeMo study population
Overall
(n= 185)
Metamorphopsia
(n= 129)
No metamorphopsia
(n= 56)
P valuea
Age (years)
Mean 72.8 72.8 72.8 0.981
SD 8.7 8.9 8.2
Gender, n (%)
Male 61 (33.0) 40 (31.0) 21 (37.5) 0.388
Female 124 (67.0) 89 (69.0) 35 (62.5)
Race, n (%)
Caucasian 167 (90.3) 115 (89.1) 52 (92.9) 0.141
Black 9 (4.9) 8 (6.2) 1 (1.8)
Asian 5 (2.7) 2 (1.6) 3 (5.4)
Other 4 (2.2) 4 (3.1) 0 (0.0)
Eye dominance, n (%)
Affected eye is
dominant
107 (57.8) 76 (58.9) 31 (55.4) 0.653
Fellow eye involvement, n (%)
VMT present in fellow
eye
32 (17.3) 21 (16.3) 11 (19.6) 0.578
Physician assessment of metamorphopsia
In affected eye 91 (49.2) 72 (55.8) 19 (33.9) 0.006
In fellow eye 21 (11.4) 16 (12.4) 5 (8.9) 0.494
Retinal exam findings in affected eyeb, n (%)
Clinically evident VMT 149 (80.5) 101 (78.3) 48 (85.7) 0.242
FTMH 42 (22.7) 35 (27.1) 7 (12.5) 0.029
Additional OCT findings in affected eyeb, n (%)
FTMH present 46 (24.9) 39 (30.2) 7 (12.5) 0.010
ERM present 18 (9.7) 13 (10.1) 5 (8.9) 0.809
Physician assessment of ocular diagnosis in affected eye, n (%)
FTMH 48 (25.9) 41 (31.8) 7(12.5) 0.006
ERM 17 (9.2) 13 (10.1) 4 (7.1) 0.526
Physician assessment of ocular diagnosis in any eye, n (%)
FTMH 55 (29.7) 47 (36.4) 8 (14.3) 0.002
ERM 25 (13.5) 20 (15.5) 5 (8.9) 0.229
Visual acuity (LogMAR)c
Affected eye, n 183 128 55 0.038
Mean (SD) 0.41 (0.30) 0.44 (0.32) 0.33 (0.25)
Fellow eye, n 176 124 52 0.371
Mean (SD) 0.28 (0.39) 0.30 (0.38) 0.24 (0.41)
Size of adhesion (microns)c
n 165 112 53 0.095
Mean (SD) 440.3 (477.5) 397.6 (408.1) 530.6 (592.6)
Size of macular hole (microns)c
n 43 36 7 0.572
Mean (SD) 236.6 (98.9) 240.4 (100.5) 217.0 (94.8)
Central/Macular subfield thickness (microns)c
n 150 104 46 0.296
Mean (SD) 334.5 (84.6) 339.3 (79.3) 323.6 (95.5)
Metamorphopsia, where presence of metamorphopsia was defined as a metamorphopsia questionnaire (MeMoQ) score > 0; No Metamorphopsia,
where absence of metamorphopsia was defined as a MeMoQ score= 0
SD standard deviation, LogMAR logarithm of the minimum angle of resolution, VMT vitreomacular traction, FTMH full-thickness macular hole,
ERM epiretinal membrane
aP values assessing difference between metamorphopsia subgroups were derived from the chi-square and Student’s t-test for categorical and
continuous variables, respectively.
bCategories not mutually exclusive; percentages may not add to 100%
cIncludes patients with measured visual acuity or OCT. Patients not included in this calculation had Unknown/Not Measured indicated on the CRF
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estimated difference between both groups were reported
including 95% CI.
A multivariate ordinary least squares (OLS) regression
was fit to identify the predictors of VFQ-25 scores,
including metamorphopsia severity score, whether the
affected eye was the best seeing eye, whether the affected
eye was the dominant eye, patient age, visual acuity of best
seeing eye (in LogMAR), visual acuity of the dominant eye
(in LogMAR). The selection of these variables was based
on clinical reasoning. Analyses were performed on patients
who had non-missing data. In the scoring of questionnaire
data, the rules surrounding missing items was applied for
each specific questionnaire.
Results
Characteristics of participants
This study included a total of 185 patients enroled at 19
hospital eye clinics (Study flow diagram in Figure S1).
Patients were predominantly female (67.0%), Caucasian
(90.3%), with a mean age of 72.8 years (standard deviation
[SD], 8.7). Almost half of the patients (46.5%) had either a
concomitant or past ocular condition and 27.6% had
undergone an ocular intervention prior to baseline
(Table S1). Demographics and clinical characteristics were
similar for patients with and without metamorphopsia,
except for the occurrence of vitrectomy in the fellow eye,
which was more frequently observed in patients with
metamorphopsia (10/129, 7.8%) than in patients without
metamorphopsia (0/56, 0%) (Table S2). The affected eye
was dominant in 57.8% of patients (Table 1). The mean
[SD] visual acuity (LogMAR) in the affected eye was 0.41
(0.30). Ocular characteristics of patients with metamor-
phopsia showed worse visual acuity (VA) (0.44; Snellen:
20/55) vs. patients without metamorphopsia (0.33; Snellen
20/43). Similarly, a concomitant FTMH was diagnosed
more frequently in patients with metamorphopsia (31.8%)
vs. patients without metamorphopsia (12.5%). Physician
assessment of the presence of symptoms of metamorphopsia
was higher in the group of patients with self-reported
metamorphopsia (55.8%) vs. the group without self-
reported metamorphopsia (33.9%). VMT in the fellow eye
was diagnosed in 17.3% of patients; an ERM was diagnosed
in 9.2% of affected eyes.
Self-reported prevalence and severity of
metamorphopsia
The prevalence and severity of metamorphopsia was based on
the patient’s subjective perception of metamorphopsia as
evaluated using the MeMoQ questionnaire, a self-assessed
and self-administered questionnaire. The overall self-reported
prevalence of metamorphopsia was 69.7% (95% CI 62.6,
76.3%) and higher among patients with a concomitant FTMH
(85.4%; 95% CI 72.2, 93.9%) vs. patients with no FTMH
(64.2%; 95% CI 55.6, 72.2%; Figure S2). When a FTMH was
present the severity was higher (0.66; SD: 0.63) vs. patients
with no FTMH (0.36; SD: 0.52; Figure S3).
Agreement between self-reported (MeMoQ) and
physician assessed presence of metamorphopsia
The patient’s perception of metamorphopsia was based on
the results of the MeMoQ, and self-reported (Fig. 1). The
physician assessment of metamorphopsia was based on the
physician asking the patient if he/she experienced any
visual symptoms (metamorphopsia, blurred vision, curvy
objects, double vision, unable to drive at night, other), in the
affected or fellow eye (Figure S4 symptom-based ques-
tionnaire). The presence of metamorphopsia according to
the physician’s assessment of symptoms was 53.0% (95%
CI 45.5, 60.3%) and higher in patients with (59.7%; 95% CI
50.7, 68.2%) vs. patients without metamorphopsia (37.5%;
95% CI 24.9, 51.5%; Figure S5).
Consistent with the MeMo study objective, the pre-
valence of metamorphopsia (69.7%) was primarily based on
self-reported perception of subjective symptoms of meta-
morphopsia. Furthermore, physicians assessed the presence
of metamorphopsia symptoms, denoted as distorted vision
and/or curvy objects in any eye, which was lower (53.0%).
The agreement between self-reported (MeMoQ) and phy-
sician assessment (symptom-based) of the presence/absence
of metamorphopsia was concordant in 112 patients (60.5%).
(In 77 patients the self-reported assessment on the presence
of metamorphopsia agreed with the physician’s and in 35
patients the self-reported assessment on the absence of
metamorphopsia agreed with the physician’s assessment).
The assessment of metamorphopsia status was discordant in
73 (52+ 21) patients (39.5%). The Kappa statistic mea-
suring the difference between observed and expected
agreement (by chance alone) was 0.192 (95% CI 0.058–
0.326) indicating a slight agreement (Table 2).
Vision-related quality of life
Vision-related quality of life was self-assessed by the
patient and based on results of the VFQ-25 questionnaire
(self-administered version). VRQoL, as measured by the
VFQ-25 composite score was 85.1 points in the overall
population and was markedly lower in patients with meta-
morphopsia (82.3) vs. patients without metamorphopsia
(91.4; Figure S6). For individual domains, the largest dif-
ference in mean scores between both subgroups was
observed for near activities (metamorphopsia: 75.3, No
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metamorphopsia: 90.2, difference: 14.9). Differences for
distance activities and mental health were 11.3 (75.4 vs.
86.7) and 11.0 points (81.0 vs. 92.0), respectively (Fig. 2).
The smallest difference in mean score (4.8 points) was
observed for colour vision (95.2 vs. 100; Figure S6).
Overall, mean scores were noticeably lower (indicating
poorer VRQoL) in patients with vs. patients without
metamorphopsia for all domains (P < .05), except for the
driving subscale and general health item VFQ-25
(Figure S6).
Impact of metamorphopsia on vision‐related quality
of life
Based on the univariate model that examined the impact of
the presence of metamorphopsia on VFQ-25, the mere
presence of metamorphopsia was associated with a sig-
nificantly lower VFQ-25 score. The mean VFQ-25 com-
posite score for patients with metamorphopsia was 82.3
(95% CI 79.8, 84.9) vs. 91.4 (95% CI 87.5, 95.3) for
patients without metamorphopsia. Therefore, the disutility
associated with the presence of metamorphopsia was −9.1
(95% CI −13.7, −4.4; P < .001).
Subgroup analyses further investigated the presence of
concomitant FTMH or ERM on these quality of life find-
ings. More specifically, 121 patients had an isolated VMT
(no FTMH, no ERM) in the affected eye, while 64 patients
had a concomitant FTMH or ERM. Results indicate that
quality of life (as measured by the VFQ-25 composite
score) was lower in VMT patients when metamorphopsia
was present (82.90, n= 76) compared to patients without
metamorphopsia (90.99, n= 45). This difference of 8.09
points was significant (P= 0.0015). Similar findings were
observed in patients with a concomitant FTMH or ERM:
quality of life in patients with metamorphopsia was 81.54
(n= 53) compared with 93.12 (n= 11) in patients without
metamorphopsia. This difference of 11.58 points was sig-
nificant (P= 0.046). A similar analysis using any-eye level
data confirmed that the presence of metamorphopsia
significantly impacts vision-related QoL regardless of the
ocular diagnosis (Table S3).
Predictors of vision‐related quality of life
The OLS regression model estimated the effect of the
different covariates on VFQ-25 composite score
(Table 3). The variables that were significantly associated
with lower VFQ-25 scores were severity of metamor-
phopsia (P < 0.001) and patient age (P < 0.05). Each unit
increase in metamorphopsia severity score was associated
with a 14.5-point reduction in the VFQ-25 composite
score. Each additional 10 years in patient’s age was
associated with 3-point reduction in VFQ-25. VA of
the best seeing eye was marginally predictive of VFQ-25
(P= 0.086).
Table 2 Agreement between
patient and physician assessment
of metamorphopsia
Self-reported assessment (MeMoQ-based)
Metamorphopsia No metamorphopsia Total
Physician assessment (symptom-
based)
Metamorphopsia 77 21 98
No Metamorphopsia 52 35 87
129 56 185
Agreement between self-reported and physician assessment of metamorphopsia
Physician assessment: Assessment of metamorphopsia symptoms denoted as presence of distorted vision
and/or curvy objects, in any eye; Patient assessment: Self-reported presence of metamorphopsia, defined as a
MeMoQ score > zero (N= 129). Values in bold represent agreement (77+ 35) between patient and
physician assessment. Values in italic represent disagreement (52+ 21) between patient and physician
assessment
Fig. 2 Main VFQ-25 subscales by presence of metamorphopsia
Descriptive statistics for the main VFQ-25 subscales were generated
for the study population by self-reported presence of metamorphopsia.
P values assessing differences between metamorphopsia subgroups
were derived from the Student’s t-test. Mean scores were noticeably
lower (indicating poorer VRQoL) in patients with vs. patients without
metamorphopsia for the main VFQ-25 subscales (P < .05)
P. J. Patel et al.
Discussion
In patients with VMT, metamorphopsia is considered one of
the cardinal symptoms which impairs a patient in the ability
to perform activities such as reading, face recognition,
cooking, watching television and driving. This study shows
that 69.7% of patients with VMT attending NHS hospital
eye clinics in the UK reported the presence of metamor-
phopsia. The prevalence was notably higher among VMT
patients with a concomitant FTMH (85.4%) compared to
patients with no FTMH (64.2%). Patients who self-reported
metamorphopsia had a noticeably lower VRQoL compared
to patients with no metamorphopsia (a 9.1-point decrease on
the VFQ-25 composite score). Moreover, the independent
effect of the severity of metamorphopsia, over and above
VRQoL decrements due to reduced VA, is an important
finding indicating that despite controlling for vision, meta-
morphopsia impacts the quality of vision.
The present literature reveals a paucity of data on the
prevalence and severity of metamorphopsia self-reported by
patients with VMT. Indeed, there are no prospective reports
from multi-centre settings relating to metamorphopsia in
VMT in clinical practice. However, the recent interest in
pharmacotherapy for the treatment of VMT generated data
relating to symptoms and VRQoL in VMT from clinical
trials. The OASIS study [20] was a multi-centre clinical trial
of ocriplasmin for the treatment of VMT and the prevalence
of metamorphopsia (detected using Amsler grid testing) was
70.2% in patients with VMT only, compared with 92.1% in
VMT patients with a concomitant FTMH [21]. The MeMo
study was an observational study of routine practice and
metamorphopsia testing was not routinely measured in
clinical practice in a measurable objective way. It is inter-
esting however how similar the self-reported prevalence of
metamorphopsia was in the MeMo study, using the MeMo
questionnaire, as compared to Amsler testing in the OASIS
study. The numerically higher prevalence reported in the
OASIS study compared to the MeMo study may result from
differences in measurement tools (Amsler grid vs. self-
reported MeMoQ), settings (clinical trial vs. usual clinical
practice) and differences in patient characteristics.
One major finding in the MeMo study is the discordance
in self-reported presence of metamorphopsia using the
MeMoQ versus patient-reported symptoms on questioning
by the ophthalmologist. When metamorphopsia was diag-
nosed based on the ophthalmologist’s assessment of
symptoms of distorted vision and/or curvy objects in any
eye, rather than patient self-assessment, the prevalence was
lower (53.0%). Both the presence of metamorphopsia and
VRQoL were self-reported and reflect a patient-level (not
eye-specific) assessment. Similarly, physicians assessed
symptoms in affected and fellow eye. The analysis of
agreement between physician and self-reported assessments
used data for any eye, hence, the discordance cannot be
attributed to a mono vs. binocular assessment. Several
factors may underlie this disparity including misinterpreta-
tion of the questions posed by the ophthalmologist, differ-
ences between physicians’ questions and the MeMoQ, or
patients feeling unsure whether to disclose the full extent of
symptoms. Disparities between patients and physicians in
reporting or describing symptoms have been reported pre-
viously, including retinal disorders [22, 23].
Our results show impaired VRQoL using the VFQ-25 in
patients with recently diagnosed VMT. The MIVI-TRUST
clinical programme reported a mean baseline VFQ-25
composite score of 82 points for placebo-treated and 77.1
for ocriplasmin-treated patients [24]. This VMT population
was further characterised by a mean baseline BCVA of 64.3
letters, a markedly high prevalence of ERM (38.7%), and a
presence of a concomitant FTMH in 23.5% of patients
Table 3 Multivariate regressions
of independent predictors for
VR-QoL
Independent variable Parameter
Estimate
Standard
error
Lower 95%
CI
Upper 95%
CI
P value
Intercept 114.31 9.18 96.19 132.44 <0.001
Affected eye is best seeing eyea −4.82 2.78 −10.31 0.68 0.086
Affected eye is dominant eyea 2.65 2.44 −2.17 7.46 0.279
Patient ageb −0.3 0.12 −0.55 −0.06 0.016
Visual acuity of best seeing eye
(in LogMAR) b
−2.19 3.91 −9.9 5.56 0.580
Visual acuity of dominant eye (in
LogMAR) b
−4.22 4.62 −13.36 4.91 0.362
Metamorphopsia severity scoreb −14.55 1.95 −18.4 −10.69 <0.001
A parsimonious model refers to the simplest plausible model with the fewest possible number of variables.
No automatic variable selection methods were employed since explorative models include many variables
that are highly correlated
aValue: yes vs. no
bValue: continuous
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compared to a mean VA of 64.5 letters (0.41 LogMAR),
13.5 % of patients with ERM and 25.9% with FTMH in the
MeMo study [25]. Despite these differences between the
MIVI-TRUST and the MeMo population, our results show
that the VFQ-25 composite score observed in the MeMo
group is reasonably consistent with the VFQ-25 findings by
Stalmans et al.
After adjusting for baseline VA, age, and other clinically
important variables, the severity of metamorphopsia was the
most predictive of impaired VRQoL. These results may
under-estimate the full impact of metamorphopsia since the
multivariate analysis controls for VA and other variables
that may in themselves be affected by metamorphopsia.
Nevertheless, the results underscore the importance of
metamorphopsia as a predictor for VRQoL in patients with
VMT. Surprisingly, the involvement of the dominant eye
did not appear to affect VRQoL. This could be because the
measurement of dominance is influenced by the pathology
(i.e., less reliable if one eye is affected) or due to the crude
method of assessment of eye dominance used in clinical
practice.
A number of previous studies have assessed the severity
of metamorphopsia in other retinal disorders, using Amsler
grid, M-CHARTS and/or PHP, and found that changes in
the severity of metamorphopsia was an important factor of
changes in VRQoL [6–8, 10–12]. It could be postulated that
the impact of metamorphopsia on VRQoL is similar
regardless of the cause of the retinal disorder, though pre-
vious studies have not assessed metamorphopsia and its
association with VRQoL in patients with VMT.
In the MeMo study, a diagnosis of VMT was reported in
17% of fellow eyes (bilateral affection), and physicians
assessed the presence of symptoms of metamorphopsia in
11% of fellow eyes. Impairment in VRQoL could partially
be attributed to VMT or macular pathology in the fellow
eye, however, based on the results of the multivariate
regression analysis adjusting for covariates such as fellow
eye involvement did not significantly affect the impact of
metamorphopsia on VFQ-25 composite scores. In addition,
subgroup analyses confirmed that the presence of meta-
morphopsia significantly impacted vision-related quality of
life both in patients with isolated VMT as well as in patients
with a concomitant FTMH or ERM.
The MeMo study is the first prospective study using the
questionnaire developed by Arimura et al. to assess meta-
morphopsia based on self-reported perception of abnormal
vision quality.
This study has several strengths, including the use of a
prospective, multi-centre study design with large sample
size and the collection of rich phenotypic data including
information from SD-OCT imaging as well as patient-
centred reporting of metamorphopsia and VRQoL. The
limitations include the lack of use of a wider range of
methods to quantify the severity of metamorphopsia due to
the time limitations on patients and clinicians in real-world
clinical settings (absence of a validated instrument for the
clinical evaluation of metamorphopsia at the time of study
design). Indeed, at a feasibility study at the time of the
MeMo study design confirmed unanimously that diagnostic
tools to detect metamorphopsia in the UK NHS eye clinics,
such as Amsler grid, were not used in clinical practice
because of their inability to quantify the degree of meta-
morphopsia. In addition, no validated tool was available or
adopted in UK clinical practice, meaning the introduction of
such objective measurement instrument would have altered
real life (observational) practice. Additional research to
detect and assess metamorphopsia with validated tools is
warranted to investigate the correlation between the
patient’s perception of the severity of metamorphopsia and
an objective quantification. Although reading vision is a key
component in the assessment of metamorphopsia, an
important limitation of our study was the absence of this
assessment. Indeed, near vision function was affected in
close to half of the patients. Further research to include an
assessment of full visual function performance such as
reading acuity or contrast sensitivity is warranted. Finally,
the MeMo study population was restricted to patients with a
FTMH diameter smaller than or equal to 400 µm, to be
consistent with the population studied in the ocriplasmin
clinical trials. Although this may restrict generalisability of
the results, it allows better comparability with the existing
evidence on VFQ-25 outcomes in VMT patients eligible for
pharmacological treatment.
In summary, the MeMo Study is a large prospective
patient-centred study reporting the prevalence and severity
of self-reported metamorphopsia and its independent effect
on VRQoL in patients recently diagnosed with VMT
attending hospital eye clinics in the UK. The results show
that metamorphopsia is a highly prevalent symptom, parti-
cularly in those with a concomitant FTMH, and impairs
VRQoL independent of the presence of a FTMH and
reduced VA. Given the importance of metamorphopsia as a
symptom in patients with VMT, it is important to consider
the impact of new and existing treatments on this disabling
symptom. Further research supporting a full psychometric
evaluation of the questionnaire in populations with retinal
disorders, including VMT is warranted.
Summary
What was known before
● A small number of studies have reported the prevalence
of metamorphopsia (distorted vision) and its association
with impaired vision-related quality of life (VRQoL) in
retinal disorders.
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● None of these relate to metamorphopsia in patients with
vitreomacular traction (VMT).
What this study adds
● Metamorphopsia is a common symptom of abnormal
vision in patients recently diagnosed with VMT, and is a
predictor of impaired quality of life, over and above
quality of life decrements due to reduced visual acuity.
Increasing severity of metamorphopsia and age were
associated with a poorer vision related quality of life,
independently of visual acuity.
● Metamorphopsia was reported more frequently when
using a metamorphopsia-specific patient questionnaire
as compared to symptom-based assessment by the
ophthalmologist.
● Given the importance of metamorphopsia as a symptom
in patients with VMT, the use of a patient-reported
questionnaire to detect symptoms of metamorphopsia
may be considered in clinical practice.
Acknowledgements The authors would like to acknowledge the
MeMo study teams and clinical site investigators at the following
participating sites, for their important and significant contribution in
the study conduct, data collection and overall study management: Dr.
Winfried Amoaku (Nottingham University Hospitals NHS Trust); Dr.
Ben Burton (James Paget University Hospitals NHS Foundation
Trust); Dr. Edward Doyle (South Devon Healthcare NHS Foundation
Trust); Mr. Timothy Jackson (King’s College Hospital NHS Foun-
dation Trust); Mr. Robert Johnston (Gloucestershire Hospitals NHS
Foundation Trust); Dr. Zachariah Koshy (Ayrshire and Arran Health
Board, NHS Scotland); Dr. Mo Majid (University Hospitals Bristol
NHS Foundation Trust); Dr. Simon Morgan (University Hospitals of
Morecambe Bay NHS Foundation Trust); Dr. Nishal Patel (East Kent
Hospitals University NHS Foundation Trust); Dr. Praveen J. Patel
(Moorfields Eye Hospital NHS Foundation Trust); Dr. Niall Patton
(Central Manchester University Hospitals NHS Foundation Trust); Dr.
Mustansir Siddique (University Hospital of North Staffordshire NHS
Trust); Mr. Theodor Stappler (Royal Liverpool and Broadgreen Uni-
versity Hospitals NHS Trust); Mr. David Steel (City Hospitals Sun-
derland NHS Foundation Trust); Dr. Simon Taylor (Royal Surrey
County Hospital NHS Foundation Trust); Dr. Elridge Thompson
(Southend University Hospital NHS Foundation Trust); Mr. Ajai
Tyagi (Sandwell and West Birmingham Hospitals NHS Trust); Prof.
Yit Yang (Royal Wolverhampton NHS Trust); Dr. Rahila Zakir
(Imperial College Healthcare NHS Trust). Marco Tangelder provided
epidemiological input during the study conduct, data management and
analysis. Esmeralda Meunier provided statistical input in the analysis
plan and data management. Lawrence Rasouliyan performed parts of
the statistical analysis.
Funding The study was funded and supported by Oxurion NV. The
sponsor contributed to the design and conduct of the study, data
management and analysis.
Author contributions BL conceived of the study. PJP and BL drafted
the manuscript. PJP, CH, JB and BL participated in the study design
and conduct. PJP and DS contributed to the acquisition of the data and
AA to the analysis of the data. All authors had access to the data and
participated in the data analyses and interpretation of the study results.
All authors contributed to the writing of the manuscript, read and
approved the final manuscript.
Compliance with ethical standards
Conflict of interest Dr. Praveen J. Patel reports grants (to institution)
from Oxurion NV during the conduct of the study. Dr. Christoph
Hirneiß, Prof. John Brazier report consultation fees from Oxurion NV
during the conduct of the study. Abdalla Aly reports employment by
Pharmerit International that received consultation fees from Oxurion
NV for the analysis of the data. Benedicte Lescrauwaet reports con-
sultation fees from Oxurion NV during the conduct of the study and
outside the submitted work.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel
E, et al. The International Vitreomacular Traction Study Group
classification of vitreomacular adhesion, traction, and macular
hole. Ophthalmology. 2013;120:2611–9.
2. Jackson TL, Nicod E, Simpson A, Angelis A. Symptomatic
vitreomacular adhesion. Retina. 2013;33:1503–11.
3. García-Layana A, García-Arumí J, Ruiz-Moreno JM, Arias-
Barquet L, Cabrera-López F, Figueroa MS. A review of current
management of vitreomacular traction and macular hole. J Oph-
thalmol. 2015;2015:809640.
4. Johnson MW. Posterior vitreous detachment: evolution and
complications of its early stages. Am J Ophthalmol.
2010;149:371–1.
5. Gandorfer A, Rohleder M, Kampik A. Epiretinal pathology of
vitreomacular traction syndrome. Br J Ophthalmol. 2002;86:902–
9.
6. Lina G, Xuemin Q, Qinmei W, Lijun S. Vision-related quality of
life, metamorphopsia, and stereopsis after successful surgery for
rhegmatogenous retinal detachment. Eye. 2016;30:40–5.
7. Fukuda S, Okamoto F, Yuasa M, Kunikata T, Okamoto Y, Hir-
aoka T, et al. Vision-related quality of life and visual function in
patients undergoing vitrectomy, gas tamponade and cataract sur-
gery for macular hole. Br J Ophthalmol. 2009;93:1595–9.
8. van de Put MAJ, Vehof J, Hooymans JMM, Los LI. Postoperative
metamorphopsia in macula-off rhegmatogenous retinal detach-
ment: associations with visual function, vision related quality of
life, and optical coherence tomography findings. Arch Neurol.
1998;55:1362–8.
9. Okamoto Y, Okamoto F, Hiraoka T, Oshika T. Vision-related
quality of life and visual function following intravitreal bev-
acizumab injection for persistent diabetic macular edema after
vitrectomy. Jpn J Ophthalmol. 2014;58:369–74.
Patient-reported prevalence of metamorphopsia and predictors of vision-related quality of life in. . .
10. Matsuoka Y, Tanito M, Takai Y, Koyama Y, Nonoyama S, Ohira
A. Visual function and vision-related quality of life after vitrect-
omy for epiretinal membranes: a 12-month follow-up study.
Invest Ophthalmol Vis Sci. 2012;53:3054–8.
11. Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Vision-
related quality of life and visual function after vitrectomy for
various vitreoretinal disorders. Invest Ophthalmol Vis Sci Assoc
Res Vision Ophthalmol. 2010;51:744–51.
12. Okamoto F, Okamoto Y, Hiraoka T, Oshika T. Effect of vitrect-
omy for epiretinal membrane on visual function and vision-related
quality of life. Am J Ophthalmol. 2009;147:869–74–874.e1.
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=
pubmed&id=19200531&retmode=ref&cmd=prlinks.
13. Ghazi-Nouri SMS, Tranos PG, Rubin GS, Adams ZC, Charteris
DG. Visual function and quality of life following vitrectomy and
epiretinal membrane peel surgery. Br J Ophthalmol. 2006;90:
559–62.
14. Midena E, Vujosevic S. Metamorphopsia: an overlooked visual
symptom. Ophthalmic Res Karger Publ. 2015;55:26–36.
15. Kim JW, Kim YT. Clinical application of 3D display device in
ophthalmology: measurement of metamorphopsia. Acta Ophthal-
mol. 2016;94:e54–8.
16. Arimura E, Matsumoto C, Nomoto H, Hashimoto S, Takada S,
Okuyama S, et al. Correlations between M-CHARTS and PHP
findings and subjective perception of metamorphopsia in patients
with macular diseases. Invest Ophthalmol Vis Sci. 2011;52:
128–35.
17. Mangione CM. Development of the 25-list-item National Eye
Institute Visual Function Questionnaire. Arch Ophthalmol Am
Med Assoc. 2001;119:1050–8.
18. RAND C. The National Eye Institute 25-item Visual Function
Questionnaire (VFQ-25). 2000:1–15. https://www.rand.org/hea
lth/surveys_tools/vfq.html. Accessed June 30, 2017.
19. Viera AJ, Garrett JM. Understanding interobserver agreement: the
kappa statistic. Fam Med. 2005;37:360–3.
20. Dugel PU, Tolentino M, Feiner L, Kozma P, Leroy A. Results of
the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreo-
macular Adhesion Including Macular Hole (OASIS) Randomized
Trial. Ophthalmology. 2016;123:2232–47.
21. OASIS Clinical Study Report, Data om File, ThromboGenics.
22. Patty L, Wu C, Torres M, Azen S, Varma R, Los Angeles Latino
Eye Study Group. Validity of self-reported eye disease and
treatment in a population-based study: the Los Angeles Latino Eye
Study. Ophthalmology. 2012;119:1725–30.
23. Popovic M, Chaudhary V, McKay BR, Moinul P, Mohaghagh M,
Beattie A, et al. Discrepancies in physician–patient agreement in
reporting ocular history. Can J Ophthalmol. 2016;51:378–81.
24. Varma R, Haller JA, Kaiser PK. Improvement in patient-reported
visual function after ocriplasmin for vitreomacular adhesion:
results of the microplasmin for intravitreous injection-traction
release without surgical treatment (MIVI-TRUST) trials. JAMA
Ophthalmol. 2015;133:997–1004.
25. Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola
S, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular
traction and macular holes. N Engl J Med. 2012;367:606–15.
P. J. Patel et al.
